Imaging Study to Investigate Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Suspected Prostate Cancer Recurrence (SPOTLIGHT)

Inclusion Criteria:

Patient is male and aged >18 years old.
History of localized adenocarcinoma of the prostate with prior curative intent treatment.

An elevated PSA, clinically suspicious for biochemically recurrent disease:

Following Radical Prostatectomy: PSA >0.2 ng/mL
Following Radiotherapy: nadir +2 ng/mL.
Potentially eligible for salvage therapy with curative intent.

Exclusion Criteria:

Patients who are planned to have an x-ray contrast agent or other PET radiotracer <24 hours prior to the PET scan.
Patients currently receiving Androgen Deprivation Therapy (ADT).